Shopping Cart
- Remove All
- Your shopping cart is currently empty
Timolumab (BTT 1023), a fully human antibody targeting vascular adhesion protein-1 (VAP-1), attenuates fibrosis in a mouse model of liver injury and may be used to study primary sclerosing cholangitis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $263 | In Stock | |
5 mg | $795 | In Stock | |
10 mg | $1,260 | In Stock | |
25 mg | $1,870 | In Stock | |
50 mg | $2,520 | In Stock |
Description | Timolumab (BTT 1023), a fully human antibody targeting vascular adhesion protein-1 (VAP-1), attenuates fibrosis in a mouse model of liver injury and may be used to study primary sclerosing cholangitis. |
In vitro | Timolumab binds to human VAP-1, thereby inhibiting it from functioning as an adhesion molecule. It also recognizes VAP-1 from other primates and rabbits, but does not cross-react to VAP-1 from rats and mice. [2] |
Alias | BTT1023, BTT 1023; Anti-Human AOC3 Recombinant Antibody, BTT 1023 |
Cas No. | 1073538-99-4 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.